ArticleScientific reports2026
A novel oxidation strategy using a palladium nanocatalyst for stabilizing bisacodyl in polyethylene glycol suppositories.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research aimed to stabilize the bisacodyl molecule (a stimulant laxative) within a polyethylene glycol (PEG) base matrix for suppository formulation. Bisacodyl is sensitive to acidic conditions, and the use of conventional PEG bases, due to their weakly acidic nature, leads to drug instability. On the other hand, alternative bases such as Witepsol are not economically viable due to their high cost. In this study, a novel method for the chemical modification of PEG to remove its acidic property is presented. This modification was achieved through an oxidation process using the organopalladium Nano catalyst UMCM-1-NH2-F2C-Pd. The efficacy of this catalyst in oxidizing PEG and creating stability in the suppository structure was evaluated. The results indicate that the oxidized PEG, having lost its acidic characteristics, provides a compatible and stable base for bisacodyl suppository formulation. This solution not only maintains the chemical stability of the drug but also offers favorable economic justification for industrial production due to the cost-effectiveness of PEG. Therefore, the application of the designed Nano catalyst is introduced as an effective method to overcome the chemical and economic limitations in the production of bisacodyl suppositories.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.